News Desk
Daily coverage of the 2026 peptide regulatory wave — FDA action, PCAC proceedings, compounding pharmacy industry moves, telehealth pivots, and clinical research developments.
Regulatory · Market · Research · RSS
- market
Post-April 15, Where You Live Matters More Than You Think
Federal peptide reclassification sets the floor; state pharmacy boards set the ceiling. Ten states plus DC keep restrictive regimes that add real friction.
Apr 29, 2026
- market
The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC
GLP-1 telehealth providers have the prescribers, compounding ties, and DTC marketing muscle to dominate peptides after PCAC. Who's positioning, and the impact.
Apr 28, 2026
- research
BPC-157: What the Research Actually Shows (And What It Doesn't)
BPC-157 has the strongest practitioner reputation of the reclassified peptides. An honest read on preclinical breadth, human trial gaps, and what it means.
Apr 27, 2026
- regulatory
Why the Research-Chemical Gray Market Is Not Going Away (And What to Do About It)
The April 15 reclassification cleared the prescription path for peptides. It did nothing to address the research-chemical channel — which is more dangerous now.
Apr 26, 2026
- regulatory
What the July 23–24 PCAC Meeting Will Actually Decide
The July PCAC meeting will determine final 503A Bulks List placement for the twelve reclassified peptides. The three possible outcomes and what each means.
Apr 25, 2026
- market
Compounding Pharmacies Quietly Positioning Ahead of July PCAC Meeting
The 90 days between the April 15 peptide reclassification and the July PCAC meeting are when the supply chain repositions. What's happening, and why it matters.
Apr 24, 2026
- regulatory
FDA Removes 12 Therapeutic Peptides From Category 2 — What the April 15 Action Means
The FDA's April 15 reclassification opens a legal compounding path for BPC-157, TB-500, and 10 other peptides. What it does — and doesn't — change.
Apr 23, 2026